Zoetis (ZTS) Tops Q4 EPS by 4c; Affirms FY16 EPS Guidance
Get Alerts ZTS Hot Sheet
Join SI Premium – FREE
Zoetis (NYSE: ZTS) reported Q4 EPS of $0.43, $0.04 better than the analyst estimate of $0.39. Revenue for the quarter came in at $1.3 billion versus the consensus estimate of $1.25 billion.
GUIDANCE:
Zoetis sees FY2016 EPS of $1.71-$1.81, versus the consensus of $1.81. Zoetis sees FY2016 revenue of $4.65-4.775 billion, versus the consensus of $4.82 billion.
In 2015, Zoetis continued to affirm our reputation as the global leader in the animal health industry with a strong financial performance, ongoing investments in our future growth, and a commitment to creating value for our customers and our shareholders,” said Juan Ramón Alaix, Chief Executive Officer at Zoetis. “In our three years as a public company, we have been delivering consistent operational revenue growth, and we expect our 2015 growth to show once again that we are growing faster than the industry.”
“We also grew our adjusted net income faster than sales as we focus on greater efficiency in our business,” continued Alaix. “We continue to have confidence in our end markets, business model, new product launches, improved product supply and progress toward our efficiency goals. Despite the negative impacts of foreign currency and Venezuela, we are pleased to reaffirm our 2016 and 2017 guidance for adjusted earnings per share, which was updated in January to reflect the European Commission tax decision.”
“We delivered 6% operational revenue growth in the fourth quarter, which is particularly notable as compared against a strong fourth quarter of 2014,” said Paul Herendeen, Chief Financial Officer at Zoetis. “Our commitment to improving the efficiency of our operations – expenses were down 8% operationally in the quarter – enabled us to grow adjusted net income by 29% operationally.”
“Our industry and our company continue to grow despite turbulence in parts of the global economy. For 2015, we delivered operational revenue growth of 8%, extending our history of growing faster than the animal health market,” said Herendeen. “The same drivers that made 2015 a financial success for Zoetis -- a resilient and growing animal health industry, new products, lifecycle innovations, business development activities and fast-paced improvements to our cost structure -- give us great confidence in our future.”
For earnings history and earnings-related data on Zoetis (ZTS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can-Fite BioPharma (CANF) Reports FY23 Results, Issues Clinical Update
- Walgreens Boots Alliance (WBA) tops Q2 expectations, narrows full-year profit forecast
- VNET Group (VNET) Tops Q4 EPS by 18c, provides guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!